Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
20 June, 09:00-11:00 EST / 14:00-16:00 BST / 15:00-17:00 CET
Agenda:
9.00 – 9.05
Introduction
9:05 – 9:40
Newly Diagnosed AML
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.
Jorge Cortes – ASCO 7027
Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.
Joshua Mitchell – ASCO 7029
Real-world effectiveness and safety of cpx-351 in patients aged <60 and ≥60 years with newly diagnosed acute myeloid leukemia: crest-UK post-hoc analysis
Priyanka Mehta – EHA 486
Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus Venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).
Jayastu Senapati – ASCO 7047
Panel discussion
09:40 – 10:10
FLT3
Azacitidine, Venetoclax and Gilteritinib for patients with newly diagnosed FLT3-mutated Acute Myeloid Leukemia: A subgroup analysis from a Phase II Study
Nicholas Short – EHA P485
Preliminary results of QUIWI: a double blinded, randomized clinical trial comparing standard chemotherapy plus Quizartinib versus placebo in adult patients with newly diagnosed flt3-itd wild-type AML
Pau Montesinos – EHA S130
BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor Gilteritinib as post-transplant maintenance for FLT3-ITD AML
Mark Levis – EHA PF251
Panel discussion
10:10 – 10:35
Venetoclax-based regimens
Addition of Venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian Cooperative analysis.
Alfonso Piciocchi – ASCO Abstract 7013
Long-Term Outcomes of Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax + HMA Therapies
Keith Pratz – EHA P525
Panel discussion
10:35 – 11:35
IO/Novel/Early Phase
A first-in-human study of CD123 NK cell engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high-risk myelodysplasia.
Anthony Stein – ASCO 7005
A Phase I/II study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in combination with Standard of care in patients with Myeloid malignancies (Bexmab) –
Mika Kontro – EHA P542
Interim Analysis of a Registration Enabling Study of Pivekimab Sunirine (PVEK, IMGN632) A CD123-targeting antibody-drug conjugate, in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDC)
Naveen Pemmaraju – EHA S139
Activity, tolerability, and resistance profile of the Menin inhibitor Ziftomenib in adults with relapsed/refractory NPM1-mutated AML
Amir Fathi – EHA LB2713
Olutasidenib in post-Venetoclax Patients with mutant LDH1 AML
Jorge Cortes – EHA P555
Panel discussion
11:35-11:40
Conclusions and meeting close